Cure My Disease

Don't miss your cure!

 Log in / Sign up

New combo treatment aims to slash sepsis deaths in HIV patients

NCT ID NCT07332325

Not yet recruiting Disease control Sponsor: University of Virginia Source: ClinicalTrials.gov ↗

First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This phase 3 trial tests whether adding a steroid (hydrocortisone) and a stronger mix of antibiotics to standard care can improve survival in HIV patients with sepsis in sub-Saharan Africa. The study will enroll 344 adults and measure how many are alive after 28 days. It aims to address the high death rate from sepsis in this region, often driven by tuberculosis and drug-resistant bacteria.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance
Hydrocortisone and a combination of antibiotics (rifampin, isoniazid, linezolid, levofloxacin)
What this could lead to
If successful, this could establish a new standard treatment for sepsis in HIV-endemic regions, potentially saving many lives.
What could go wrong
This is a single trial in a specific region and population. Results may not apply elsewhere, and the added drugs carry risks like side effects or drug interactions.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for HIV INFECTION are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

HIV infectious disease infectious disease with sepsis Sepsis tuberculosis

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

SEPSIS TUBERCULOSIS

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

Locations

  • Fort Portal Regional Referral Hospital

    Fort Portal, Uganda

    Contact Phone: •••-•••-•••• Email: •••••@•••••

    Contact

  • Kibong'oto Infectious Diseases Hospital

    Sanya Juu, Tanzania

    Contact Phone: •••-•••-•••• Email: •••••@•••••

    Contact Phone: •••-•••-•••• Email: •••••@•••••

    Contact

  • Mbarara Regional Referral Hospital

    Mbarara, Uganda

    Contact Phone: •••-•••-•••• Email: •••••@•••••

    Contact

  • Sekou Toure Regional Referral Hospital

    Mwanza, Tanzania

    Contact Phone: •••-•••-•••• Email: •••••@•••••

    Contact

More trials for these conditions

Other studies related to the condition(s) this trial covers.